

**Journal of Pharmaceutical Research International**

**2022**

Certificate No.: SDI/HQ/PR/Cert/83438/DWI

**Certificate of Excellence in Reviewing**

awarded to

**Dwi Murtiasutik**

Airlangga University, Indonesia

*In recognition of an outstanding contribution to the quality of the Journal.*

Date: 23-Feb-2022



Dr. M Basumondal  
Chief Managing Editor

Reg. Office:

India: Guest House Road, Street no. 1/6, Hooghly, West Bengal, India. Tele: +91 861752708. UK: Third Floor, 207 Regent Street, London, W1B 3HH, UK. Fax: +44 20-3031-1429



# Certificate for Reviewing the Manuscript-Dwi Murtiastutik



23 Februari 2022 19:56

editor.sumita2@gmail.com

Rincian



Certificate...8/DWI.pdf  
529 KB (100%)

Simpan

Dear Dr. Dwi Murtiastutik,

Thank you for your help and support to maintain the high peer review standard of this journal. Kindly find herewith the certificate of reviewing. We



Balas

Balas s

Terusk

Hapus

Lagi

Nada dering



Journal

UI

UNIVERSITAS



Dear Dr. Dwi Murtiastutik,

Thank you for your help and support to maintain the high peer review standard of this journal. Kindly find herewith the certificate of reviewing. We again thank you for your great help.

Please note that this Certificate has no relationship with Publons record and enrolment. For Publons reviewer record, please follow the guideline as mentioned in the respective website.

One line of acknowledgement will be highly appreciated.

With regards,  
Dr. Basu

Journal editorial office

Reg. Offices:

India: Guest House Road, Street no - 1/6, Hooghly, West Bengal, India, Tele: +91 8617752708 | +91 9163821242

UK: Third Floor, 207 Regent Street, London, W1B 3HH, UK, Fax: +44 20-3031-1429

Disclaimer: This email and any files transmitted with it are confidential and intended solely for the use of the individual or entity to whom they are addressed. If verification is required please request a signed hard-copy/scanned version. Our company accepts no liability for the content of this email, unless that information is subsequently confirmed in writing.





Simpan sebagai PDF

Salinan: 01      Ukuran kertas:



Dear Dr. Dwi Murtiastutik,

This mail is in continuation of my last mail. We are sure that you are aware of the excellent initiative taken by Publons, which aims to speed up research by harnessing the power of peer review.

They provide a platform that allows researchers to track, verify and be recognised for their peer review and editorial work. A researcher's peer review and editorial contributions can be displayed on their public Publons profile to show the world the impact they have on their research field and enhance their career.

Publons rewards you for documenting your review history by providing you with a verified record which you can use in funding and promotion campaigns.

It is very easy and will take hardly 3-5 minutes time. Kindly please follow the below mentioned steps

1. Create your account here: <https://publons.com/account/signup/>
2. Forward your review receipts (i.e. "thank you for reviewing" emails from journals like our last mail) to [reviews@publons.com](mailto:reviews@publons.com)

You can see helpful guideline here:

<https://publons.freshdesk.com/support/solutions/folders/12000006431>

**Please be safe during this COVID-19 pandemic situation. We wish best of health for you and your family members.**

Thank you very much for spending your valuable time.

With Best Regards  
Ms. Ruma Bag

Journal editorial office

Reg. Offices:

India: Guest House Road, Street no - 1/6, Hooghly, West Bengal, India, Tel: +91 8617752708 | +91 9163821242 WhatsApp: +91 8617752708

UK: Third Floor, 207 Regent Street, London, W1B 3HH, UK, Fax: +44 20-3031-1429

EMP-003-TP

On Tue, 1 Feb 2022 at 10:47, dwimurtiastutik  
<[dwimurtiastutik@yahoo.co.id](mailto:dwimurtiastutik@yahoo.co.id)> wrote:





92% 06:13



Simpan sebagai PDF

Salinan: 01 Ukuran kertas:



**\*\*This is an automated email. If you have already contacted us about the submission, please ignore this reminder.\*\***

Dear Dr Murtiastutik,

On 30 December 2022 we sent you the invitation shown below. Please could you accept or decline the invitation as soon as possible, by clicking on the link?

Original email:

**\*\*The contents of this email are confidential.\*\***

Ref: Submission ID f25a1972-fe8e-439b-9bb4-5e93ab1d737f

Dear Dr Murtiastutik,

BMC Oral Health has received a manuscript that I'd like to invite you to review, as you have published related work yourself. You'll find the details appended underneath this email.

Please accept or decline the manuscript using the link below. Should you choose to decline, you'll be given the option to recommend alternative reviewers, which would be greatly appreciated.

Kind regards,

Paolo Boffano  
Editorial Board Member  
BMC Oral Health

To accept or decline the manuscript, please use this link:  
<https://reviewer-feedback.springernature.com/review-invitation/280da37c-4f98-449a-80e0-6bb87bdfc2f0>

If you wish to contact us about the manuscript, please email [bmcoralhealth@biomedcentral.com](mailto:bmcoralhealth@biomedcentral.com).

Submission details

Authors:  
Ragnhild Elisabeth Monsen, Anne Karin Kristoffersen, Caryl Gay, Bente Brokstad Herlofson, Katrine Gahre Fjeld, Lene Hystad Hove, Hilde Nordgarden, Anita Tollisen, Anners Lerdal, Morten Enersen





# Simpan sebagai PDF

Salinan: 01      Ukuran kertas:



**Title:**

"Identification and susceptibility testing of oral candidiasis in advanced cancer patients"

**Abstract:**

**Background:** Patients with advanced cancer are prone to develop different opportunistic oral infection due to anti-cancer treatment or the malignancies themselves. Studies of oral fungal samples show an increased prevalence of non-*Candida albicans* species in mixed oral infections with *Candida albicans*. Non-*C. albicans* and *C. albicans* are associated with varying degrees of resistance to azoles, which may have implications for treatment. This study aimed to assess the diversity and antifungal susceptibility of *Candida* species detected in the oral cavity.

**Methods:** An observational study with microbiological analysis was conducted. Clinical fungal isolates were collected from patients in a hospice unit in 2014–2016. Isolates were re-grown on chromID® *Candida* plates in 2020. Single colony of each species was re-cultivated and prepared for biochemical identification with a VITEK2® system and verified by gene sequencing. Etest was performed on RPMI agar, and the antifungals fluconazole, amphotericin B, anidulafungin and nystatin were applied.

**Results:** Fifty-six isolates from 45 patients were identified. Seven different *Candida* species and one *Saccharomyces* species were detected. The results of biochemical identification were confirmed with sequencing analysis. Thirty-six patients had mono infection, and nine out of 45 patients had 2-3 different species detected. Of *C. albicans* strains, 39 out of 40 were susceptible to fluconazole. Two non-*C. albicans* species were resistant to fluconazole, one to amphotericin B and three to anidulafungin.

**Conclusion:** *C. albicans* was the predominant species, with a high susceptibility to antifungal agents. Different *Candida* species occur in both mono and mixed infections. Identification and susceptibility testing may therefore lead to more effective treatment and may prevent the development of resistance among patients with advanced cancer.

**Trail registration:** The study Oral Health in Advanced Cancer was registered at ClinicalTrials.gov (#NCT02067572) in 20/02/2014.


To accept or decline the manuscript, please use this link:

<https://reviewer-feedback.springernature.com/review-invitation/280da37c-4f98-449a-80e0-6bb87bdfc2f0>

Reviewing for BMC Oral Health

BMC Oral Health is committed to providing a rapid and fair review process.





So, if you decide to accept the manuscript, we would hope to receive your report within 10 days.

We operate a transparent peer review process, which means we will publish your report with the article under an Open Access Creative Commons CC-BY 4.0 License. For even greater transparency, you can opt to have your name included on your review. You will be given this option when you submit your report.

The editorial board and publishing team of BMC Oral Health are not able to anticipate all potential competing interests, so we ask you to draw our attention to anything that might affect your review, and to decline submissions where it may be hard to remain objective.

If you review this manuscript you will be eligible for a 15% discount on one article processing charge for a manuscript submitted to one of the subject-specific journals in the BMC series (<http://www.biomedcentral.com/p/the-bmc-series-journals#journalist>) or BMC Research Notes. This must be claimed on submission of the manuscript and is available for one year from completion of your review. Only one discount can be claimed on a submitted manuscript and cannot be combined with any other discounts.

If you would prefer us not to contact you in the future, please let us know by emailing [bmcoralhealth@biomedcentral.com](mailto:bmcoralhealth@biomedcentral.com).



# Simpan sebagai PDF



Salinan: 01      Ukuran kertas:



Complete manuscript and Review Form are available below.

<https://review.oacademicpress.com/82221>

Password- Jfeiofewf(9k)nkdfdPP

If you cannot download this file and if you require the file as E-mail attachment kindly let us know.

## 2. Benefits for Reviewers

**2.1 Certificate of peer reviewing:** After completion of timely quality peer review, we'll be pleased to provide you official Certificate of peer reviewing (signed Scan copy). Please see a sample certificate here: <http://ditdo.in/cert/AJDS.jpg>

**2.2 Publons:** This journal is included in Publons (Link: <https://tinyurl.com/publons-AJDS>), a part of Web of Science Group. After completion of peer review, you'll get all the credit of your review works, which may help you officially in your academic career, promotion, research grants, etc.

**2.3 Nomination for "Reviewer of the Month":** After completion of timely quality peer review, you will be nominated for the "Reviewer of the Month" competition. Winners of the competition will get prestigious "Reviewer of the Month" certificate (signed Scan copy).

**2.4 DOI reference for reviewer credit:** If the paper is accepted for publication by the editor after peer review, then your name will be included in the front page of the published paper as reviewer. Then you can officially write the DOI number of the paper and title of the paper in your CV as part of your reviewer credit.

**2.5 Annual Peer Reviewers' Hall of Fame (APR-HF 2020)\*:** Extraordinary reviewers will be included in "Annual Peer Reviewers' Hall of Fame". Photograph and short biography of selected reviewers will be published in APR-HF. This is an internationally circulated book with print and online ISBN numbers and DOI number. APR-HF book is promoted by Digital news channels, social media, scientific blog; you tube channel, digital press release, etc. (Link: <http://www.scholarshof.com>)

